
Publication|Articles|December 30, 2024
Peers & Perspectives in Oncology
- December II, 2024
- Pages: 76
Roundtable Roundup: Relapsed CLL After 2 Prior Lines
Author(s)Targeted Oncology Staff
Fact checked by: Dylann Bailey
In separate, live virtual events, Alvaro Jose Alencar, MD, and Michael E. Williams, MD, discussed third-line options for a patient with relapsed/refractory chronic lymphocytic leukemia (CLL).
Advertisement
- CASE SUMMARY
- A 65-year-old man who was diagnosed with CLL in 2019 presented to his oncologist at routine follow-up.
- Medical history: type 2 diabetes controlled with insulin
- Patient received previous treatments with:
- First line: acalabrutinib (Calquence) monotherapy
- Achieved good clinical response over 3 years but later progressed on therapy
- Second line: venetoclax (Venclexta) plus rituximab (Rituxan)
- Completed 24-month treatment regimen
- Was in treatment-free interval for 6 months
- Due to disease progression, his hemoglobin has dropped over the past 3 months and is currently at 10 g/dL.
- At follow-up, the patient is now aged 70 years and does not report any symptoms yet.
- ECOG performance status: 0
Articles in this issue
about 1 year ago
Managing Intermediate-Risk Myelofibrosis With RuxolitinibAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
5



















